| Q35073133 | 2002 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: implications for emergency department practice |
| Q81585447 | 2004 American College of Cardiology/American Heart Association guidelines for the management of patients with ST-elevation myocardial infarction: implications for emergency department practice |
| Q57630301 | 2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease |
| Q30586557 | 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Associ |
| Q57630298 | 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Associa |
| Q42643914 | A call to ACTION (acute coronary treatment and intervention outcomes network): a national effort to promote timely clinical feedback and support continuous quality improvement for acute myocardial infarction |
| Q40179672 | A community traffic safety analysis of pedestrian and bicyclist injuries based on the catchment area of a trauma center. |
| Q79508459 | A comparison of acute coronary syndrome care at academic and nonacademic hospitals |
| Q30574099 | A contemporary view of diagnostic cardiac catheterization and percutaneous coronary intervention in the United States: a report from the CathPCI Registry of the National Cardiovascular Data Registry, 2010 through June 2011. |
| Q39002609 | A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease |
| Q40150943 | A framework for quality improvement: an analysis of factors responsible for improvement at hospitals participating in the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Gu |
| Q54578648 | A new era in secondary prevention after acute coronary syndrome. |
| Q80870686 | A practical guide to understanding the 2002 ACC/AHA guidelines for the management of patients with non-ST segment elevation acute coronary syndromes |
| Q39904575 | A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study |
| Q44683742 | A randomized, placebo-controlled trial of early eptifibatide for non-ST-segment elevation acute coronary syndromes |
| Q79913098 | Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery |
| Q36320553 | Acute coronary syndromes and diabetes mellitus |
| Q88139790 | Acute coronary syndromes: Treatment for low-risk patients with STEMI--challenges remain |
| Q91968393 | Administrative claims data to support pragmatic clinical trial outcome ascertainment on cardiovascular health |
| Q34154285 | Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry |
| Q84562230 | Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time |
| Q91213464 | Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial |
| Q93074505 | Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial |
| Q58480968 | Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome |
| Q92535620 | Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial |
| Q46090587 | An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence |
| Q38813966 | An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome |
| Q31032618 | An international comparison of patients undergoing percutaneous coronary intervention: A collaborative study of the National Cardiovascular Data Registry (NCDR) and Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies (JCD-KiCS). |
| Q79632716 | Anatomic distribution of the culprit lesion in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: findings from the National Cardiovascular Data Registry |
| Q92420483 | Androgen deprivation therapy and cardiovascular disease |
| Q84705281 | Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention |
| Q44808979 | Antianginal therapy before percutaneous coronary intervention |
| Q34502912 | Antimicrobial resistance markers of class 1 and class 2 integron-bearing Escherichia coli from irrigation water and sediments |
| Q92086657 | Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease |
| Q38742687 | Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis |
| Q42970462 | Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry |
| Q114066683 | Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab |
| Q39161550 | Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial |
| Q36484993 | Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome |
| Q38849393 | Assessment of Operator Variability in Risk-Standardized Mortality Following Percutaneous Coronary Intervention: A Report From the NCDR. |
| Q91588911 | Association Between Cardiac Catheterization Laboratory Pre-Activation and Reperfusion Timing Metrics and Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Report From the AC |
| Q39768278 | Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial |
| Q83202050 | Association between hospital process performance and outcomes among patients with acute coronary syndromes |
| Q44103066 | Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. |
| Q92961570 | Association of Cognitive Impairment With Treatment and Outcomes in Older Myocardial Infarction Patients: A Report From the NCDR Chest Pain-MI Registry |
| Q58129718 | Association of Gout With Long-Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease |
| Q47222907 | Association of acute kidney injury and chronic kidney disease with processes of care and long-term outcomes in patients with acute myocardial infarction |
| Q90827612 | Association of acute myocardial infarction cardiac arrest patient volume and in-hospital mortality in the United States: Insights from the National Cardiovascular Data Registry Acute Coronary Treatment And Intervention Outcomes Network Registry |
| Q54458227 | Association of body mass index and long-term outcomes in older patients with non-ST-segment-elevation myocardial infarction: results from the CRUSADE Registry. |
| Q45035244 | Association of chronic lung disease with treatments and outcomes patients with acute myocardial infarction |
| Q45738848 | Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention |
| Q37587785 | Association of early physician follow-up and 30-day readmission after non-ST-segment-elevation myocardial infarction among older patients |
| Q46361916 | Association of evidence-based care processes and outcomes among patients with acute coronary syndromes: performance matters |
| Q34428736 | Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative |
| Q81278510 | Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction |
| Q90146028 | Associations of osteopontin and NT-proBNP with circulating miRNA levels in acute coronary syndrome |
| Q30699883 | Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry |
| Q43226646 | Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications |
| Q48672802 | Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial |
| Q37156100 | Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score |
| Q53494879 | Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. |
| Q57483754 | Better Outcomes for Patients Treated at Hospitals That Participate in Clinical Trials |
| Q33520617 | Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry |
| Q44440753 | Blood pressure paradox in patients with non-ST-segment elevation acute coronary syndromes: results from 139,194 patients in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the Amer |
| Q30844067 | Carbenoxolone induced depression of rhythmogenesis in the pre-Bötzinger Complex |
| Q85893959 | Cardiac Troponin and Risk Stratification in Ischemic Heart Disease |
| Q30918687 | Cardiac arrest and clinical characteristics, treatments and outcomes among patients hospitalized with ST-elevation myocardial infarction in contemporary practice: A report from the National Cardiovascular Data Registry |
| Q30686916 | Cardiac biomarker measurement after elective percutaneous coronary interventions in older patients: insights from the National Cardiovascular Data Registry |
| Q48349453 | Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction |
| Q38730184 | Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effort |
| Q26853015 | Cardiovascular care facts: a report from the national cardiovascular data registry: 2011 |
| Q38424497 | Cardiovascular drug development: is it dead or just hibernating? |
| Q80931335 | Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative |
| Q34094289 | Careers for clinician investigators |
| Q80147666 | Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes |
| Q34683098 | Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) init |
| Q51012555 | Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). |
| Q35562152 | Changing the model of care for patients with acute coronary syndromes |
| Q47386203 | Characteristics and in-hospital outcomes of patients presenting with non-ST-segment elevation myocardial infarction found to have significant coronary artery disease on coronary angiography and managed medically: stratification according to renal fu |
| Q36626647 | Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention |
| Q45876195 | Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction undergoing an invasive strategy according to hemoglobin levels |
| Q44993927 | Characteristics and outcomes in patients undergoing percutaneous coronary intervention following cardiac arrest (from the NCDR). |
| Q80232541 | Characteristics, management, and outcomes of 5,557 patients age > or =90 years with acute coronary syndromes: results from the CRUSADE Initiative |
| Q30725922 | Characteristics, management, and outcomes of cocaine-positive patients with acute coronary syndrome (from the National Cardiovascular Data Registry). |
| Q59356047 | Characterization and outcomes of women and men with non–ST-segment elevation myocardial infarction and nonobstructive coronary artery disease: Results from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with |
| Q40414727 | Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes |
| Q79842977 | Characterizing young patients with diabetes and non-ST-segment elevation acute coronary syndromes |
| Q61870407 | Chronic Kidney Disease in Patients with Non–ST-Segment Elevation Acute Coronary Syndromes |
| Q91817259 | Circulating MicroRNA Profiling in Non-ST Elevated Coronary Artery Syndrome Highlights Genomic Associations with Serial Platelet Reactivity Measurements |
| Q91281555 | Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials |
| Q54759394 | Class 1 and class 2 integrons in poultry carcasses from broiler house and poultry processing environments. |
| Q74269900 | Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) |
| Q79849797 | Clinical characteristics, process of care, and outcomes of Hispanic patients presenting with non-ST-segment elevation acute coronary syndromes: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Ear |
| Q61667798 | Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization |
| Q83888285 | Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention |
| Q30844989 | Clinical trial participation after myocardial infarction in a national cardiovascular data registry |
| Q45212087 | Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome |
| Q47691483 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial |
| Q48794256 | Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy |
| Q28196442 | Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge |
| Q46714811 | Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes |
| Q28195722 | Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial |
| Q44912669 | Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion |
| Q33415791 | Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). |
| Q91716864 | Comparative Effectiveness of β-Blocker Use Beyond 3 Years After Myocardial Infarction and Long-Term Outcomes Among Elderly Patients |
| Q95940059 | Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52,816 Patients from 12 Randomized Trials |
| Q45971184 | Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative. |
| Q94586717 | Comparison of Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction With Versus Without Hyperuricemia or Gout |
| Q38942247 | Comparison of Delay Times from Symptom Onset to Medical Contact in Blacks Versus Whites With Acute Myocardial Infarction |
| Q39666309 | Comparison of Long-Term Mortality of Patients Aged ≤40 Versus >40 Years With Acute Myocardial Infarction |
| Q30983150 | Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). |
| Q50685933 | Comparison of baseline characteristics, treatment patterns, and in-hospital outcomes of Asian versus non-Asian white Americans with non-ST-segment elevation acute coronary syndromes from the CRUSADE quality improvement initiative. |
| Q56944673 | Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention |
| Q46185004 | Comparison of clinical characteristics, treatments and outcomes of patients with ST-elevation acute myocardial infarction with versus without new or presumed new left bundle branch block (from NCDR®). |
| Q44278667 | Comparison of long-term outcomes between older Asian and white patients with non-ST-segment elevation myocardial infarction: findings from CRUSADE-CMS database |
| Q30766493 | Comparison of percutaneous coronary intervention for previously treated versus de novo culprit lesions in acute myocardial infarction patients: insights from the National Cardiovascular Data Registry |
| Q39766012 | Comparison of performance on Hospital Compare process measures and patient outcomes between hospitals that do and do not participate in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines |
| Q43247857 | Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). |
| Q39638421 | Comparison of the prognostic value of peak creatine kinase-MB and troponin levels among patients with acute myocardial infarction: a report from the Acute Coronary Treatment and Intervention Outcomes Network Registry-get with the guidelines. |
| Q42373680 | Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes |
| Q49972080 | Comprehensive electrocardiogram-to-device time for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: A report from the American Heart Association mission: Lifeline program |
| Q50244980 | Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition |
| Q87853566 | Contemporary Patterns of Early Coronary Angiography Use in Patients With Non-ST-Segment Elevation Myocardial Infarction in the United States: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes |
| Q38793797 | Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease |
| Q33568223 | Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry |
| Q30842297 | Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). |
| Q45340643 | Contemporary use of adjunctive thrombectomy during primary percutaneous coronary intervention for ST-elevation myocardial infarction in the United States |
| Q92346632 | Continued investigator engagement: Reasons principal investigators conduct multiple FDA-regulated drug trials |
| Q37226395 | Continuum of care in the treatment of ST-segment elevation myocardial infarction (STEMI): importance of platelet and coagulation inhibition |
| Q43227261 | Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention |
| Q57243287 | Corrigendum to “A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease” [Am Heart J 181 (2016) 92–100] |
| Q94545447 | Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial |
| Q44737159 | Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials |
| Q44777043 | Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes |
| Q44592712 | Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report |
| Q41467009 | Cumulative incidence of death and rehospitalization among the elderly in the first year after NSTEMI. |
| Q28166395 | Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies |
| Q36328631 | Data monitoring committees: Promoting best practices to address emerging challenges |
| Q90613054 | Days Alive and Out of Hospital: Exploring a Patient-Centered, Pragmatic Outcome in a Clinical Trial of Patients With Acute Coronary Syndromes |
| Q84587695 | Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward |
| Q46127315 | Delay from symptom onset to hospital presentation for patients with non-ST-segment elevation myocardial infarction |
| Q51558217 | Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction. |
| Q96232659 | Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting |
| Q44127086 | Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapies |
| Q59186935 | Development of Systems of Care for ST-Elevation Myocardial Infarction Patients |
| Q36469645 | Diagnostic time course, treatment, and in-hospital outcomes for patients with ST-segment elevation myocardial infarction presenting with nondiagnostic initial electrocardiogram: a report from the American Heart Association Mission: Lifeline program |
| Q39416285 | Differences in Short- and Long-Term Outcomes Among Older Patients With ST-Elevation Versus Non-ST-Elevation Myocardial Infarction With Angiographically Proven Coronary Artery Disease |
| Q46160461 | Differences in short-term versus long-term outcomes of older black versus white patients with myocardial infarction: findings from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of A |
| Q54615572 | Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification: A report from NCDR. |
| Q96031954 | Differential Longitudinal Outcomes Following Percutaneous Coronary Intervention to the Left Internal Mammary Artery and Other Bypass Grafts of the LAD: Findings From the NCDR |
| Q38689627 | Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome |
| Q30991505 | Direct Transfer From the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry |
| Q33873652 | Direct myocardial revascularization and angiogenesis--how many patients might be eligible? |
| Q46794302 | Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry |
| Q42656977 | Do patients treated at academic hospitals have better longitudinal outcomes after admission for non-ST-elevation myocardial infarction? |
| Q80031055 | Documented traditional cardiovascular risk factors and mortality in non-ST-segment elevation myocardial infarction |
| Q41422471 | Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome |
| Q33774818 | Door-to-balloon times for patients with ST-segment elevation myocardial infarction requiring interhospital transfer for primary percutaneous coronary intervention: a report from the national cardiovascular data registry |
| Q98244184 | Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference |
| Q39550267 | Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial. |
| Q47742996 | Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization |
| Q30800602 | Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry |
| Q52590010 | Early discontinuation of prasugrel or clopidogrel in acute coronary syndromes: insights from the TRILOGY ACS trial. |
| Q81702355 | Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns |
| Q43278686 | Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care. |
| Q44420954 | Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. |
| Q73749792 | Early use of glycoprotein IIb/IIIa inhibitors in the ED treatment of non-ST-segment elevation acute coronary syndromes: a local quality improvement initiative |
| Q92708835 | Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome |
| Q92223274 | Effect of Alirocumab on Mortality After Acute Coronary Syndromes |
| Q91213357 | Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES |
| Q91303099 | Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis |
| Q39091664 | Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial |
| Q44546026 | Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). |
| Q96588163 | Effect of intervention timing on one-year mortality in elderly non-ST-segment elevation myocardial infarction patients |
| Q43571946 | Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study |
| Q40825574 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients |
| Q37095212 | Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry). |
| Q36799394 | Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis |
| Q92990025 | Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery |
| Q91619662 | Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial |
| Q92241544 | Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial |
| Q38448455 | Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel |
| Q94950873 | Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX |
| Q46861395 | Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials |
| Q43491089 | Emergency department bypass for ST-Segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline program |
| Q33663306 | Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors |
| Q73288573 | Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators |
| Q51745125 | Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. |
| Q30870018 | Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry |
| Q52395527 | Evaluating the safety effects of bicycle lanes in New York City. |
| Q46754037 | Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative |
| Q51826453 | Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. |
| Q51687073 | Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. |
| Q31151437 | Executive Summary: Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries |
| Q51593584 | Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently ve |
| Q47948293 | Factors associated with off-label use of drug-eluting stents in patients with ST-elevation myocardial infarction |
| Q30875802 | Fibrinolysis use among patients requiring interhospital transfer for ST-segment elevation myocardial infarction care: a report from the US National Cardiovascular Data Registry |
| Q50279616 | Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. |
| Q42166770 | Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes |
| Q46397522 | Frequency and consequences of recording an electrocardiogram >10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative). |
| Q33724941 | Frequency and predictors of drug-eluting stent use in saphenous vein bypass graft percutaneous coronary interventions: a report from the American College of Cardiology National Cardiovascular Data CathPCI registry |
| Q44019132 | Frequency of nonsystem delays in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention and implications for door-to-balloon time reporting (from the American Heart Association Mission: Lifeline program). |
| Q90759681 | Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials |
| Q51353466 | Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. |
| Q37331201 | G-protein-coupled receptors as signaling targets for antiplatelet therapy |
| Q40938991 | Gaps in referral to cardiac rehabilitation of patients undergoing percutaneous coronary intervention in the United States |
| Q33392834 | Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). |
| Q43148501 | Gender differences in the treatment of non-ST-segment elevation myocardial infarction |
| Q33841478 | Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. |
| Q50142514 | Guideline implementation research: exploring the gap between evidence and practice in the CRUSADE Quality Improvement Initiative |
| Q47697188 | Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH™ patient registry |
| Q47679901 | Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Corona |
| Q59356154 | Heart Failure With Preserved Left Ventricular Systolic Function Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes |
| Q54698914 | Helmet use is associated with safer bicycling behaviors and reduced hospital resource use following injury. |
| Q37448857 | Hospital length of stay in patients with non-ST-segment elevation myocardial infarction |
| Q92987608 | Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry |
| Q46320987 | Hospital patterns of medical management strategy use for patients with non-ST-elevation myocardial infarction and 3-vessel or left main coronary artery disease |
| Q37151458 | Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes |
| Q34994933 | Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. |
| Q39967642 | Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel |
| Q35135852 | Impact of Human Development Index on the profile and outcomes of patients with acute coronary syndrome |
| Q93008228 | Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions |
| Q31154265 | Impact of Sex and Contact-to-Device Time on Clinical Outcomes in Acute ST-Segment Elevation Myocardial Infarction-Findings From the National Cardiovascular Data Registry |
| Q40127312 | Impact of Society of Cardiovascular Patient Care accreditation on quality: an ACTION Registry®-Get With The Guidelines™ analysis |
| Q36902479 | Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction |
| Q34095167 | Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-Segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). |
| Q41528609 | Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial |
| Q83961616 | Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes |
| Q87643932 | Impact of diabetes mellitus on clinical characteristics, management, and in-hospital outcomes in patients with acute myocardial infarction (from the NCDR) |
| Q46461630 | Impact of home warfarin use on the treatment and outcomes of patients undergoing percutaneous coronary intervention |
| Q46692006 | Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative |
| Q50454126 | Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. |
| Q46675751 | Impact of time of presentation on process performance and outcomes in ST-segment-elevation myocardial infarction: a report from the American Heart Association: Mission Lifeline program |
| Q51568237 | Implications and reasons for the lack of use of reperfusion therapy in patients with ST-segment elevation myocardial infarction: findings from the CRUSADE initiative. |
| Q44055690 | Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction |
| Q44771218 | Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction |
| Q47108813 | Improvement in Care and Outcomes for Emergency Medical Service-Transported Patients With ST-Elevation Myocardial Infarction (STEMI) With and Without Prehospital Cardiac Arrest: A Mission: Lifeline STEMI Accelerator Study |
| Q81749016 | Improvements in quality improvement |
| Q91178636 | Improving and sustaining the site investigator community: Recommendations from the Clinical Trials Transformation Initiative |
| Q28194111 | Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative |
| Q51504080 | In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry®-GWTG™. |
| Q30840892 | In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry |
| Q85317125 | Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction |
| Q39962038 | Incidence and predictors of stroke associated with percutaneous coronary intervention |
| Q33384251 | Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice |
| Q57483632 | Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non–ST-elevation acute coronary syndromes undergoing diagnostic angiography |
| Q89129053 | Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome |
| Q38102355 | Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches |
| Q84368801 | Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and |
| Q30838979 | Independent data monitoring committees: preparing a path for the future |
| Q37481596 | Indications, algorithms, and outcomes for coronary artery bypass surgery in patients with acute coronary syndromes |
| Q81703458 | Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes |
| Q43175938 | Influence of clinical trial participation on subsequent antithrombin use. |
| Q59637609 | Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non–ST-segment elevation myocardial infarction |
| Q40181935 | Influence of inpatient service specialty on care processes and outcomes for patients with non ST-segment elevation acute coronary syndromes |
| Q48393088 | Influence of presenting electrocardiographic findings on the treatment and outcomes of patients with non-ST-segment elevation myocardial infarction |
| Q28211543 | Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non-ST-segment elevation acute coronary syndromes |
| Q43900299 | Influence of transfer-in rates on quality of care and outcomes at receiving hospitals in patients with non-ST-segment elevation myocardial infarction |
| Q46504683 | Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial |
| Q74184374 | Initial experience with multivessel percutaneous coronary intervention during mechanical reperfusion for acute myocardial infarction |
| Q79372504 | Insurance coverage and care of patients with non-ST-segment elevation acute coronary syndromes |
| Q34805549 | Integrating GP IIb/IIIa inhibition into treatment strategies for acute ST-elevation myocardial infarction. |
| Q35625416 | Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes |
| Q97899109 | Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial |
| Q33958587 | International comparisons of the management of patients with non-ST segment elevation acute myocardial infarction in the United Kingdom, Sweden, and the United States: The MINAP/NICOR, SWEDEHEART/RIKS-HIA, and ACTION Registry-GWTG/NCDR registries |
| Q50647596 | Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. |
| Q43562471 | Left and codominant coronary artery circulations are associated with higher in-hospital mortality among patients undergoing percutaneous coronary intervention for acute coronary syndromes: report From the National Cardiovascular Database Cath Percut |
| Q38182003 | Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease |
| Q94703862 | Lessons learned from the CRUSADE National Quality Improvement Initiative |
| Q97562289 | Leveraging electronic health record data for pragmatic randomized trials |
| Q87447206 | Limitations of using cardiac catheterization rates to assess the quality of care for patients with non-ST-segment elevation myocardial infarction |
| Q45253561 | Lipid management in patients with unstable angina pectoris and non-ST-segment elevation acute myocardial infarction (from CRUSADE). |
| Q39807120 | Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry |
| Q99628245 | Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization |
| Q64932801 | Long-Term Mortality of Older Patients With Acute Myocardial Infarction Treated in US Clinical Practice. |
| Q46049965 | Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction |
| Q86736489 | Long-term outcomes after invasive management for older patients with non-ST-segment elevation myocardial infarction |
| Q54629946 | Long-term outcomes among older patients with non-ST-segment elevation myocardial infarction complicated by cardiogenic shock. |
| Q40522136 | Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY mana |
| Q36345292 | Longitudinal Risk of Adverse Events in Patients With Acute Kidney Injury After Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry |
| Q93124443 | Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry |
| Q47338261 | Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative |
| Q43483079 | Management of non-Q-wave myocardial infarction. |
| Q38995207 | Maximizing value and minimizing barriers: Patient-centered community consultation for research in emergency settings |
| Q43443880 | Medical records and quality of care in acute coronary syndromes: results from CRUSADE. |
| Q90986311 | Medication Discontinuation in the IMPROVE-IT Trial |
| Q89816592 | Meta-Analysis of Intraocular Bleeding With Dual Antiplatelet Therapy Using P2Y12 Inhibitors Prasugrel or Ticagrelor |
| Q36141930 | Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes |
| Q34522235 | Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization |
| Q47300249 | Mortality of Myocardial Infarction by Sex, Age, and Obstructive Coronary Artery Disease Status in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines). |
| Q40922622 | Multivessel vs culprit-only percutaneous coronary intervention among patients 65 years or older with acute myocardial infarction |
| Q41030753 | Nationwide Analysis of Patients With ST-Segment-Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention: Findings From the American Heart Association Mission: Lifeline Program |
| Q91287110 | Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status |
| Q38653210 | Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference |
| Q88922936 | Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry |
| Q35420896 | No association between hemoglobin A1c and in-hospital mortality in patients with diabetes and acute myocardial infarction |
| Q43810370 | Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppr |
| Q37092344 | Noninvasive, medical management for non-ST-elevation acute coronary syndromes |
| Q30372006 | Obesity and age of first non-ST-segment elevation myocardial infarction. |
| Q55233856 | One and done: Reasons principal investigators conduct only one FDA-regulated drug trial. |
| Q28169124 | One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry) |
| Q81454932 | Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) |
| Q28218094 | Optimizing platelet P2Y12 inhibition for patients undergoing PCI |
| Q37090758 | Outcomes According to Cardiac Catheterization Referral and Clopidogrel Use Among Medicare Patients With Non-ST-Segment Elevation Myocardial Infarction Discharged Without In-hospital Revascularization |
| Q38723675 | Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States |
| Q91086974 | Outcomes of Patients Receiving Downstream Revascularization After Initial Medical Management for Non-ST-Segment Elevation Acute Coronary Syndromes (From the TRILOGY ACS Trial) |
| Q90082098 | Overcoming the Risk-Treatment Paradox for Non-ST-Segment Elevation Acute Coronary Syndromes |
| Q81075984 | Overcoming the challenges facing quality-improvement strategies for non-ST-segment elevation acute coronary syndromes |
| Q92371579 | P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes |
| Q37119085 | Paradoxical use of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an international perspective from the CRUSADE Initiative and the Canadian ACS Registries I and II. |
| Q91440096 | Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT) |
| Q44660166 | Patient satisfaction and its relationship with clinical quality and inpatient mortality in acute myocardial infarction |
| Q80205443 | Patterns and implications of B-type natriuretic peptide measurement in patients with non-ST-segment elevation acute coronary syndromes |
| Q46419966 | Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes |
| Q28211512 | Patterns of aspirin dosing in non-ST-elevation acute coronary syndromes in the CRUSADE Quality Improvement Initiative |
| Q43416033 | Patterns of cardiac marker surveillance after elective percutaneous coronary intervention and implications for the use of periprocedural myocardial infarction as a quality metric: a report from the National Cardiovascular Data Registry (NCDR). |
| Q36684358 | Patterns of guideline adherence and care delivery for patients with unstable angina and non-ST-segment elevation myocardial infarction (from the CRUSADE Quality Improvement Initiative). |
| Q81539499 | Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals |
| Q46257217 | Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative). |
| Q90355110 | Patterns of use of targeted temperature management for acute myocardial infarction patients following out-of-hospital cardiac arrest: Insights from the National Cardiovascular Data Registry |
| Q28212516 | Pay for performance, quality of care, and outcomes in acute myocardial infarction |
| Q31105713 | Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry |
| Q33996370 | Percutaneous coronary intervention in native arteries versus bypass grafts in prior coronary artery bypass grafting patients: a report from the National Cardiovascular Data Registry |
| Q90727163 | Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of a Randomized Clinical Trial |
| Q28193946 | Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation |
| Q38461756 | Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy |
| Q36019811 | Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection |
| Q93024156 | Platelet inhibition to target reperfusion injury trial: Rationale and study design |
| Q36999542 | Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction |
| Q39904589 | Pooled analysis of adverse event collection from 4 acute coronary syndrome trials |
| Q97531564 | Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI |
| Q38881638 | Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials |
| Q45066266 | Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States |
| Q40058838 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization |
| Q57252716 | Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial |
| Q43663914 | Predicting long-term mortality in older patients after non-ST-segment elevation myocardial infarction: the CRUSADE long-term mortality model and risk score |
| Q38378471 | Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes |
| Q45940716 | Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. |
| Q46198445 | Predictors of reperfusion delay in patients with ST elevation myocardial infarction self-transported to the hospital (from the American Heart Association's Mission: Lifeline Program). |
| Q39475534 | Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry |
| Q43211946 | Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients |
| Q45900013 | Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. |
| Q51136527 | Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. |
| Q46000202 | Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. |
| Q33491352 | Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). |
| Q51785107 | Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with |
| Q44445340 | Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes |
| Q50448871 | Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. |
| Q32076709 | Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy |
| Q39470281 | Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy |
| Q51889376 | Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. |
| Q46232544 | Prolonged emergency department stays of non-ST-segment-elevation myocardial infarction patients are associated with worse adherence to the American College of Cardiology/American Heart Association guidelines for management and increased adverse even |
| Q40615288 | Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). |
| Q37733059 | Public sensationalism and clinical trials: how to address the challenges of science? |
| Q80870755 | Quality improvement tools designed to improve adherence to the ACC/AHA Guidelines for the care of patients with non-ST-segment acute coronary syndromes: the CRUSADE quality improvement initiative |
| Q28185249 | Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction |
| Q34703667 | Randomized trial of targeted performance feedback to facilitate quality improvement in acute myocardial infarction care |
| Q90423604 | Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial |
| Q44730223 | Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry |
| Q42990922 | Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percuta |
| Q35802903 | Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction |
| Q28265129 | Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks |
| Q38465848 | Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative |
| Q79861553 | Regional outcomes after admission for high-risk non-ST-segment elevation acute coronary syndromes |
| Q39646950 | Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial |
| Q89948736 | Rejoinder |
| Q30657607 | Relation of admission high-density lipoprotein cholesterol level and in-hospital mortality in patients with acute non-ST segment elevation myocardial infarction (from the National Cardiovascular Data Registry). |
| Q42644667 | Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction |
| Q37468769 | Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome |
| Q74485891 | Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction |
| Q36168700 | Relationship Between Cancer and Cardiovascular Outcomes Following Percutaneous Coronary Intervention |
| Q90759436 | Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention |
| Q38378213 | Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes |
| Q28191778 | Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes |
| Q37556037 | Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes |
| Q44262155 | Relationship of the distance between non-PCI hospitals and primary PCI centers, mode of transport, and reperfusion time among ground and air interhospital transfers using NCDR's ACTION Registry-GWTG: a report from the American Heart Association Miss |
| Q61634193 | Reply |
| Q88927512 | Reply: Effect of Pre-Procedural β-Blocker in Patients Undergoing Percutaneous Coronary Intervention |
| Q87398563 | Response to letter regarding article, "Emergency department bypass for ST-segment-elevation myocardial infarction patients identified with a prehospital electrocardiogram: a report from the American Heart Association Mission: Lifeline Program" |
| Q31095242 | Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Non-ST Elevation Myocardial Infarction: Insights From the National Cardiovascular Data Registry Acute Coronary Treatment and Interven |
| Q90218024 | Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease |
| Q93051217 | Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes |
| Q104109706 | Risk Factor Burden and Long-Term Prognosis of Patients With Premature Coronary Artery Disease |
| Q57630566 | Risk adjustment for in-hospital mortality of contemporary patients with acute myocardial infarction: The Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry®–Get With The Guidelines (GWTG)™ acute myocardial infarction mo |
| Q86480667 | Risk profile of clinical trial participants--reply |
| Q38398587 | Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention |
| Q46184030 | Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction |
| Q42641710 | Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Ear |
| Q84277742 | Safety countermeasures and crash reduction in New York City--Experience and lessons learned |
| Q59621772 | Seasonal and circadian patterns of myocardial infarction by coronary artery disease status and sex in the ACTION Registry-GWTG |
| Q64126238 | Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial |
| Q59356191 | Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors |
| Q37424804 | Sex differences in mortality following acute coronary syndromes |
| Q36102874 | Sharing Data from Cardiovascular Clinical Trials--A Proposal |
| Q34128493 | Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion |
| Q34104728 | Short-term outcomes of acute myocardial infarction in patients with acute kidney injury: a report from the national cardiovascular data registry |
| Q43142106 | Soluble urokinase-type plasminogen activator receptor: a useful biomarker for coronary artery disease and clinical outcomes? |
| Q30770001 | Sources of hospital-level variation in major bleeding among patients with non-st-segment elevation myocardial infarction: a report from the National Cardiovascular Data Registry (NCDR). |
| Q39910934 | Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial |
| Q34624137 | Standardized cardiovascular data for clinical research, registries, and patient care: a report from the Data Standards Workgroup of the National Cardiovascular Research Infrastructure project |
| Q87142479 | Statin Treatment by Low-Density Lipoprotein Cholesterol Levels in Patients With Non-ST-Segment Elevation Myocardial Infarction/Unstable Angina Pectoris (from the CRUSADE Registry) |
| Q57252735 | Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non–ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY |
| Q39581487 | Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome |
| Q83251951 | Survival of patients undergoing rescue percutaneous coronary intervention: development and validation of a predictive tool |
| Q88537064 | Taking the Reins on Systems of Care for ST-Segment-Elevation Myocardial Infarction Patients: A Report From the American Heart Association Mission: Lifeline Program |
| Q94528610 | Targeting Vascular Calcification in Chronic Kidney Disease |
| Q90846108 | Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation |
| Q38376674 | Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome |
| Q90255560 | Temporal Trends in Utilization of Cardiac Therapies and Outcomes for Myocardial Infarction by Degree of Chronic Kidney Disease: A Report From the NCDR Chest Pain-MI Registry |
| Q31055046 | Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data Registry's CathPCI Registry |
| Q59356171 | Temporal Trends in the Use of Early Cardiac Catheterization in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from CRUSADE) |
| Q82328820 | Temporal changes in the use of drug-eluting stents for patients with non-ST-Segment-elevation myocardial infarction undergoing percutaneous coronary intervention from 2006 to 2008: results from the can rapid risk stratification of unstable angina pa |
| Q33865395 | Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry |
| Q34272836 | Temporal trends in and factors associated with bleeding complications among patients undergoing percutaneous coronary intervention: a report from the National Cardiovascular Data CathPCI Registry |
| Q93355852 | The Association of Frailty With In-Hospital Bleeding Among Older Adults With Acute Myocardial Infarction: Insights From the ACTION Registry |
| Q40382429 | The Association of Transfer Rate From Hospitals Without Revascularization Capabilities and Mortality Risk for Older Non-ST-Segment Elevation Myocardial Infarction Patients. |
| Q30244265 | The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease |
| Q39765953 | The China Acute Myocardial Infarction (CAMI) Registry: A national long-term registry-research-education integrated platform for exploring acute myocardial infarction in China |
| Q40091191 | The Contemporary Use of Angiography and Revascularization Among Patients With Non-ST-Segment Elevation Myocardial Infarction in the United States Compared With South Korea. |
| Q74585455 | The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade |
| Q51749079 | The Efficacy of Early versus Delayed P2Y12 Inhibition in Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction : A Systematic Review and Meta-Analysis. |
| Q31082764 | The Impact of Bleeding Avoidance Strategies on Hospital-Level Variation in Bleeding Rates Following Percutaneous Coronary Intervention: Insights From the National Cardiovascular Data Registry CathPCI Registry |
| Q50131241 | The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care |
| Q114666737 | The National Cardiovascular Data Registry Data Quality Program 2020 |
| Q39029211 | The Role of Antiplatelet Therapy in Primary Prevention. A Review |
| Q43574924 | The association between smoking and long-term outcomes after non-ST-segment elevation myocardial infarction in older patients |
| Q84605677 | The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative |
| Q40615809 | The association of in-hospital guideline adherence and longitudinal postdischarge mortality in older patients with non-ST-segment elevation myocardial infarction |
| Q36162429 | The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction |
| Q44249008 | The association of myocardial infarction process of care measures and in-hospital mortality: a report from the NCDR®. |
| Q39360090 | The effect of high-risk ST elevation myocardial infarction transfer patients on risk-adjusted in-hospital mortality: A report from the American Heart Association Mission: Lifeline program |
| Q38509188 | The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations |
| Q91120929 | The impact of clinical vs administrative claims coding on hospital risk-adjusted outcomes |
| Q51932892 | The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromes. |
| Q50143778 | The impact of for-profit hospital status on the care and outcomes of patients with non-ST-segment elevation myocardial infarction: results from the CRUSADE Initiative |
| Q39626758 | The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non-ST-elevation myocardial infarction |
| Q38494900 | The impact of postrandomization crossover of therapy in acute coronary syndromes care |
| Q81353932 | The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative |
| Q79743260 | The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes |
| Q51810438 | The paradoxical use of cardiac catheterization in patients with non-ST-elevation acute coronary syndromes: lessons from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC /AHA Guid |
| Q88008650 | The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention |
| Q37046898 | The role of fibrinolytics in the prehospital treatment of ST-elevation myocardial infarction (STEMI). |
| Q43278684 | The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE. |
| Q35051753 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial |
| Q41735104 | Time to treatment as a quality metric for acute STEMI care |
| Q38395867 | Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial |
| Q80308951 | Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE) |
| Q33558046 | Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Ne |
| Q81362660 | Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes |
| Q84212803 | Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? |
| Q31063192 | Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry |
| Q43531447 | Treatment and outcomes in patients with myocardial infarction treated with acute β-blocker therapy: results from the American College of Cardiology's NCDR(®). |
| Q28194113 | Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes |
| Q88617193 | Treatment of coronary artery disease in cancer survivors: an emerging challenge |
| Q33641463 | Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective |
| Q54066541 | Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention. |
| Q40586942 | Trends in Bare-Metal Stent Use in the United States in Patients Aged ≥65 Years (from the CathPCI Registry). |
| Q31151434 | Trends in U.S. Cardiovascular Care: 2016 Report From 4 ACC National Cardiovascular Data Registries |
| Q64286466 | Trends in clinical trial investigator workforce and turnover: An analysis of the U.S. FDA 1572 BMIS database |
| Q51177094 | Trends in outcomes among older patients with non-ST-segment elevation myocardial infarction. |
| Q33520615 | Trends in the association between age and in-hospital mortality after percutaneous coronary intervention: National Cardiovascular Data Registry experience |
| Q33451107 | Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry |
| Q37188501 | Trends in use of anti-thrombotic agents and outcomes in patients with non-ST-segment elevation myocardial infarction (NSTEMI) managed with an invasive strategy |
| Q33752845 | Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get W |
| Q31133478 | US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry |
| Q88115752 | Uncovering the shroud on antiplatelet therapy for patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention |
| Q43526627 | Unfortunate impact of age on the management and outcomes of unstable angina and non-ST elevation myocardial infarction (The GUARANTEE Registry). |
| Q46548441 | Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes |
| Q96947779 | University of Pennsylvania 12th annual conference on statistical issues in clinical trials: Electronic health records in randomized clinical trials-challenges and opportunities (morning panel session) |
| Q39192624 | Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States |
| Q43774111 | Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patie |
| Q85075215 | Use of early clopidogrel by reperfusion strategy among patients presenting with ST-segment elevation myocardial infarction |
| Q33937805 | Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarction: findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With The Guideline |
| Q33523243 | Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Cor |
| Q43209310 | Use of guidelines-recommended management and outcomes among women and men with low-level troponin elevation: insights from CRUSADE. |
| Q84983268 | Usefulness of the Duke Sudden Cardiac Death risk score for predicting sudden cardiac death in patients with angiographic (>75% narrowing) coronary artery disease |
| Q89028822 | Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care |
| Q33398439 | Utilization and impact of pre-hospital electrocardiograms for patients with acute ST-segment elevation myocardial infarction: data from the NCDR (National Cardiovascular Data Registry) ACTION (Acute Coronary Treatment and Intervention Outcomes Netwo |
| Q120524261 | Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from the CRUSADE quality improvement initiative |
| Q43590434 | Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative |
| Q33711159 | Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry |
| Q38631705 | Utilization, Characteristics, and In-Hospital Outcomes of Coronary Artery Bypass Grafting in Patients With ST-Segment-Elevation Myocardial Infarction: Results From the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention O |
| Q45058968 | Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy |
| Q44657315 | Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative |
| Q80227802 | What aspects of hospital culture influence quality? |
| Q47176148 | What is the best ST-segment recovery parameter to predict clinical outcome and myocardial infarct size? Amplitude, speed, and completeness of ST-segment recovery after primary percutaneous coronary intervention for ST-segment elevation myocardial in |
| Q38822701 | Whole blood sequencing reveals circulating microRNA associations with high-risk traits in non-ST-segment elevation acute coronary syndrome |
| Q28210289 | Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Impleme |
| Q28210531 | Racial variations in treatment and outcomes of black and white patients with high-risk non-ST-elevation acute coronary syndromes: insights from CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early I |
| Q22252555 | The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American H |